References
- Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000;95:2754–9.
- Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases. Blood 1998;91:756–63.
- McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97:3390–3400.
- Spitzer TR, McAfee S, Sackstein R et al. Intentional induc-tion of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant 2000;6:309–20.
- Childs R, Clave E, Contentin N et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999;94:3234–41.
- Khouri IF, Saliba RM, Giralt SA et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001;98:3595–9.
- Petrus MJ, Williams JF, Eckhaus MA et al. An immuno-ablative regimen of fludarabine and cyclophosphamide prevents fully MHC-mismatched murine marrow graft rejection independent of GVHD. Biol Blood Marrow Transplant 2000;6:182–9.
- Fowler DH, Kurasawa K, Husebekk A et al. Cells of Th2 cytokine phenotype prevent LPS-induced lethality during murine graft-versus-host reaction. Regulation of cytokines and CD8+ lymphoid engraftment. 7 Immunol 1993; 152:1004–13.
- Krenger W, Snyder KM, Byon JC et al. Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease. 7 Immunol 1995;155:585–93.
- Gutierrez M, Chabner BA, Pearson D et al. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8—year follow-up study of EPOCH. 7 Clin Oncol2000;18:3633–42.
- Levine BL, Bernstein WB, Connors M et al. Effects of CD28costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. 7 Immunol 1997;159:5921–30.
- Deeg HJ, Flowers ME, Leisenring W et al. Cyclosporine (CSP) or CSP plus methylprednisolone for graft-versus-host disease prophylaxis in patients with high-risk lymphohemopoietic malignancies: long-term follow-up of a randomized trial. Blood 2000;96:1194–5.